These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15830705)

  • 1. Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-kappaB and p53 in breast cancer cell lines.
    Lun M; Zhang PL; Siegelmann-Danieli N; Blasick TM; Brown RE
    Ann Clin Lab Sci; 2005; 35(1):15-24. PubMed ID: 15830705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
    Yerlikaya A; Erin N
    Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
    Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
    Fahy BN; Schlieman MG; Mortenson MM; Virudachalam S; Bold RJ
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):46-54. PubMed ID: 15791457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB.
    Lun M; Zhang PL; Pellitteri PK; Law A; Kennedy TL; Brown RE
    Ann Clin Lab Sci; 2005; 35(3):251-8. PubMed ID: 16081580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
    Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1.
    Gulati AP; Yang YM; Harter D; Mukhopadhyay A; Aggarwal BB; Benzil DL; Whysner J; Albino AP; Murali R; Jhanwar-Uniyal M
    Mol Carcinog; 2006 Jan; 45(1):26-37. PubMed ID: 16267831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
    Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
    J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
    Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
    Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
    Zhang Z; Ma J; Li N; Sun N; Wang C
    Ann Thorac Surg; 2006 Jul; 82(1):243-8. PubMed ID: 16798222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
    Kamer S; Ren Q; Dicker AP
    Arch Gynecol Obstet; 2009 Jan; 279(1):41-6. PubMed ID: 18461345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Id-1 regulates Bcl-2 and Bax expression through p53 and NF-kappaB in MCF-7 breast cancer cells.
    Kim H; Chung H; Kim HJ; Lee JY; Oh MY; Kim Y; Kong G
    Breast Cancer Res Treat; 2008 Nov; 112(2):287-96. PubMed ID: 18158619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines.
    Brown RE; Lun M; Prichard JW; Blasick TM; Zhang PL
    Ann Clin Lab Sci; 2004; 34(3):251-62. PubMed ID: 15487699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of Velcade on the gene expression profiles of K562 cells: study of its molecular mechanism].
    Liao ZJ; Ma WL; Meng W; Liang S; Meng FY; Zheng WL
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar; 28(3):373-6. PubMed ID: 18359694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
    Minderman H; Zhou Y; O'Loughlin KL; Baer MR
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):245-55. PubMed ID: 17096161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kappaB and NF-Y activation in oral carcinoma cells.
    Shareef MM; Brown B; Shajahan S; Sathishkumar S; Arnold SM; Mohiuddin M; Ahmed MM; Spring PM
    Mol Cancer Res; 2008 Jan; 6(1):89-98. PubMed ID: 18234965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear factor-kappaB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone.
    Gordon AH; O'Keefe RJ; Schwarz EM; Rosier RN; Puzas JE
    Cancer Res; 2005 Apr; 65(8):3209-17. PubMed ID: 15833852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thermosensitization by parthenolide in human lung adenocarcinoma A549 cells and p53- and hsp72-independent apoptosis induction via the nuclear factor-kappaB signal pathway.
    Hayashi S; Hatashita M; Hayashi A; Matsumoto H; Shioura H; Kitai R
    Int J Mol Med; 2008 May; 21(5):585-92. PubMed ID: 18425350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.